These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 14603670)

  • 21. Exploring new treatment strategies in heart failure.
    Swedberg K
    Blood Press Suppl; 2000; 1():44-8. PubMed ID: 11059637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.
    Bhakta S; Dunlap ME
    Cleve Clin J Med; 2004 Aug; 71(8):665-73. PubMed ID: 15449762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T; Takeshita A
    Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [ACE inhibitors or AT1 receptor antagonists?].
    Riegger GA
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S37-9. PubMed ID: 10535045
    [No Abstract]   [Full Text] [Related]  

  • 25. [Comparison of candesartan, enalapril and their combination in congestive heart failure].
    Rapezzi C
    Ital Heart J Suppl; 2000 Mar; 1(3):429-30. PubMed ID: 10815278
    [No Abstract]   [Full Text] [Related]  

  • 26. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
    MMW Fortschr Med; 2003 Oct; 145(43):51. PubMed ID: 14664222
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapy of heart failure. Which patients does the AT1 blocker help?].
    Böhm M
    MMW Fortschr Med; 2003 Sep; 145(38):8. PubMed ID: 14603671
    [No Abstract]   [Full Text] [Related]  

  • 28. [Combination therapy of beta blockers for heart failure].
    Watanabe M; Hirata Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():129-33. PubMed ID: 17571376
    [No Abstract]   [Full Text] [Related]  

  • 29. The CHARM programme.
    Penston J
    Lancet; 2003 Nov; 362(9396):1678; author reply 1678-9. PubMed ID: 14630459
    [No Abstract]   [Full Text] [Related]  

  • 30. [Candesartan reduces the risk of mortality and recurrence of chronic heart failure. Important results from the CHARM study].
    Persson H; Swedberg K
    Lakartidningen; 2004 Feb; 101(9):764-6. PubMed ID: 15045839
    [No Abstract]   [Full Text] [Related]  

  • 31. The CHARM programme.
    Pechlaner C
    Lancet; 2003 Nov; 362(9396):1675-6; author reply 1678-9. PubMed ID: 14630453
    [No Abstract]   [Full Text] [Related]  

  • 32. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    McMurray JJ
    Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):128-9. PubMed ID: 16265452
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin receptor blockers in heart failure.
    Stergren J; McMurray JJ
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):171-5. PubMed ID: 14608522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combination therapy with ARB for heart failure].
    Sakata Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():123-7. PubMed ID: 17569310
    [No Abstract]   [Full Text] [Related]  

  • 36. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S; Wang D; Wilhelmsen L; Hennekens CH
    Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?
    de Zeeuw D; Lambers-Heerspink H
    J Am Soc Nephrol; 2009 Apr; 20(4):688-9. PubMed ID: 19279124
    [No Abstract]   [Full Text] [Related]  

  • 38. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Angiotensin I receptor blockers for heart failure].
    Fruhwald FM; Kickenweiz E; Zweiker R; Klein W
    Wien Med Wochenschr; 2001; 151(7-8):157-9. PubMed ID: 11450163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nebivolol in older adults with heart failure: reduced rates for seniors?
    Armstrong PW; Alexander KP
    J Am Coll Cardiol; 2009 Jun; 53(23):2159-61. PubMed ID: 19497442
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.